DIMS Institute of Medical Science, Inc.

Developers of Medium-term Carcinogenesis Bioassays in the world. / Contract safety research facility.

Mission

HOME ≫ Medium-term carcinogenesis ≫

Medium-term carcinogenesis bioassay method

中期発がん性試験

Our medium-term carcinogenesis bioassay method is based on the theory of two-stage cancer development (initiation and promotion), which has been demonstrated experimentally in many organs and is now reviewed as generally applicable in elucidating the mechanisms underlying onset of human cancer. Using this method, we at the DIMS Institute of Medical Science, Inc. can detect the carcinogenic action of a chemical substance in a relatively short time and with a high degree of reliability in collaboration with Nagoya City University.

Our current medium-term bioassays is focused on single organ such as liver, on which conclusion can be gained in 8 weeks, and other various organs include esophagus, stomach, large intestine, nasal cavity, lungs, mammary glands, thyroid, kidney, urinary bladder, and skin as well as for leukemia.

We also have a multi-organ carcinogenesis bioassay that can detect carcinogenicity, rather than concentrating only on a single organ.

These medium-term carcinogenesis bioassay system are fully supported by data and boasted of its successful results.

 

Medium-term multi-organ carcinogenesis bioassay
Medium-term skin carcinogenesis bioassay
Medium-term liver carcinogenesis bioassay

Japanese

Medium-term Carcinogenesis Bioassay/Safety Assessment for Developing Products

DIMS Institute of Medical Science, Inc.

64 Goura, Nishiazai,
Azai-cho, Ichinomiya,
Aichi 491-0113, Japan

Tel: +81-586-51-1201
Fax: +81-586-51-5634

Company Profile

Mobile site

DIMS Institute of Medical Science, Inc.スマホサイトQRコード

Access to the mobile site of DIMS. from this QR code.